Britain’s medicines regulator has approved Novavax’s Nuvaxovid vaccine as a COVID-19 booster for adults 18 and older, the U.S-based biotech company said on Wednesday.
Novavax Inc said that the Medicines and Healthcare Products Regulatory Agency (MHRA) has expanded the conditional marketing authorization for Nuvaxovid as a booster dose following a primary series of shots.
Nuvaxovid is also available for use as a booster in adults aged 18 and older in the US, European Union, Japan, Australia, New Zealand, Switzerland, and Israel.
The MHRA previously granted conditional marketing authorization for Nuvaxovid as a primary series in adults aged 18 and older in February 2022, and in adolescents aged 12 through 17 in August 2022.
